Internal Medicine, Endocrinology, Diabetes, & Metabolism · West Hollywood, CA
NPI
1891818332
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
8700 Beverly Blvd
West Hollywood, CA, 90048
Phone (310) 423-3870
Groups this clinician bills Medicare through
Medicare paid, 2024
$76K
2,316 services
Medicare patients, 2024
384
Average age 73
Drug cost, 2024
$1.4M
683 prescriptions
Company payments, 2025
$26K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Azarmindokht Khosravi was code 99213 (office e&m - established), 203 times for 156 patients. In total Azarmindokht Khosravi billed 2,316 services in 20 codes, and Medicare paid $76K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 203 | 156 | $54.72 | $11K |
| 99214 Office E&M - Established | Facility | 129 | 103 | $76.64 | $9,887 |
| 99205 Office E&M - New | Facility | 110 | 110 | $145.55 | $16K |
| 99231 Hospital E&M - Subsequent | Facility | 109 | 27 | $42.03 | $4,581 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 60 | 12 | $4.91 | $294 |
| 99204 Office E&M - New | Facility | 38 | 38 | $108.18 | $4,111 |
| 99213 Office E&M - Established | Office | 27 | 23 | $79.30 | $2,141 |
| 99215 Office E&M - Established | Facility | 23 | 20 | $118.93 | $2,735 |
| 99212 Office E&M - Established | Facility | 20 | 17 | $28.68 | $574 |
| 99204 Office E&M - New | Office | 14 | 14 | $144.69 | $2,026 |
| 99221 Hospital E&M - Initial | Facility | 13 | 13 | $64.61 | $840 |
| 96365 Intravenous Infusion, Hydration | Office | 12 | 12 | $57.84 | $694 |
| 99205 Office E&M - New | Office | 11 | 11 | $165.23 | $1,818 |
By year: 2022 $25K for 353 services; 2023 $60K for 1,053 services; 2024 $76K for 2,316 services.
Medicare prescription drug claims, 2024
In 2024, the drug Azarmindokht Khosravi prescribed most often to Medicare patients was Tymlos (Abaloparatide), with 90 prescriptions and refills. In total Azarmindokht Khosravi wrote 683 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tymlos Abaloparatide | 90 | 92 | 16 | $227K |
| Teriparatide Generic | 75 | 78 | 13 | $191K |
| Alendronate Sodium Generic | 54 | 143 | 21 | $628 |
| Forteo Teriparatide | 47 | 48 | Under 11 | $189K |
| Levothyroxine Sodium Generic | 35 | 99 | 15 | $402 |
| Crysvita Burosumab-Twza | 31 | 45 | Under 11 | $657K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 31 | 91 | 14 | $2,831 |
| Mounjaro Tirzepatide | 27 | 30 | Under 11 | $32K |
| Ozempic Semaglutide | 19 | 39 | Under 11 | $37K |
| Trulicity Dulaglutide | 16 | 21 | Under 11 | $20K |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 15 | 47 | Under 11 | $815 |
| Metformin Hcl Generic | 11 | 23 | Under 11 | $34.73 |
| Synthroid Levothyroxine Sodium | 11 | 33 | Under 11 | $1,369 |
Brand drugs: 400 claims; generic drugs: 204 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Azarmindokht Khosravi $26K ($26K in general payments such as food, travel and fees) from 5 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $17K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.